DK1985634T3 - Antistofbindende p-selectin glycoprotein-ligand 1 (PSGL-1) til anvendelse i behandling af en allergisk sygdom - Google Patents

Antistofbindende p-selectin glycoprotein-ligand 1 (PSGL-1) til anvendelse i behandling af en allergisk sygdom

Info

Publication number
DK1985634T3
DK1985634T3 DK08012718.6T DK08012718T DK1985634T3 DK 1985634 T3 DK1985634 T3 DK 1985634T3 DK 08012718 T DK08012718 T DK 08012718T DK 1985634 T3 DK1985634 T3 DK 1985634T3
Authority
DK
Denmark
Prior art keywords
cell
psgl
antibody
binding
treatment
Prior art date
Application number
DK08012718.6T
Other languages
Danish (da)
English (en)
Inventor
Lin Rong-Hwa
Wu Chung-Hsiun
Hsu Pei-Ling
Original Assignee
Abgenomics Cooeperatief U A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abgenomics Cooeperatief U A filed Critical Abgenomics Cooeperatief U A
Application granted granted Critical
Publication of DK1985634T3 publication Critical patent/DK1985634T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
DK08012718.6T 2001-08-03 2002-03-13 Antistofbindende p-selectin glycoprotein-ligand 1 (PSGL-1) til anvendelse i behandling af en allergisk sygdom DK1985634T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31019601P 2001-08-03 2001-08-03
US10/051,497 US7744888B2 (en) 2001-08-03 2002-01-18 Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
EP02733839A EP1411982B1 (en) 2001-08-03 2002-03-13 Modulators of p-selectin glycoprotein ligand 1

Publications (1)

Publication Number Publication Date
DK1985634T3 true DK1985634T3 (da) 2012-02-20

Family

ID=26729479

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08012718.6T DK1985634T3 (da) 2001-08-03 2002-03-13 Antistofbindende p-selectin glycoprotein-ligand 1 (PSGL-1) til anvendelse i behandling af en allergisk sygdom
DK02733839T DK1411982T3 (da) 2001-08-03 2002-03-13 Modulatorer af P-selectin-glycoprotein-ligand 1

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK02733839T DK1411982T3 (da) 2001-08-03 2002-03-13 Modulatorer af P-selectin-glycoprotein-ligand 1

Country Status (19)

Country Link
US (3) US7744888B2 (https=)
EP (2) EP1411982B1 (https=)
JP (3) JP4815101B2 (https=)
KR (1) KR100850731B1 (https=)
CN (2) CN101045161B (https=)
AT (2) ATE411045T1 (https=)
AU (1) AU2002305041B2 (https=)
CA (1) CA2428822C (https=)
CY (2) CY1108701T1 (https=)
DE (1) DE60229394D1 (https=)
DK (2) DK1985634T3 (https=)
ES (2) ES2316569T3 (https=)
IL (4) IL160168A0 (https=)
MX (1) MXPA04001047A (https=)
NO (2) NO333456B1 (https=)
NZ (1) NZ531199A (https=)
PT (2) PT1985634E (https=)
TW (1) TWI327070B (https=)
WO (1) WO2003013603A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7744888B2 (en) * 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) * 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
BRPI0414402A (pt) * 2003-09-15 2006-11-14 Abgenomics Corp moduladores de ligante 1 de glicoproteìna p-selectina
EP1689776A2 (en) * 2003-11-12 2006-08-16 Wisconsin Alumni Research Foundation Equine p-selectin glycoprotein ligand-1 and uses thereof
UY28886A1 (es) * 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
AU2012201999C1 (en) * 2004-05-10 2016-05-12 Abgenomics Cooperatief U.A. Antibodies
ES2655833T3 (es) * 2004-05-11 2018-02-21 AbGenomics Coöperatief U.A. Epítopos que inducen la muerte de células T
WO2007033959A2 (en) * 2005-09-19 2007-03-29 Vib Vzw Use of p-selectin glycoprotein ligand 1 in modulation of hematogenous metastasis of lymphomas
US20070160601A1 (en) * 2005-12-09 2007-07-12 Angela Widom Neutralizing antibodies against primate psgl-1 and uses therefor
US7833530B2 (en) * 2008-05-15 2010-11-16 Selexys Pharmaceuticals Corporation Methods of inhibiting the PSGL-1-mediated adhesion and chemokine-mediated migration with PSGL-1-specific antibodies
ES2387156B1 (es) * 2010-12-01 2013-07-04 Universidad Autónoma de Madrid Uso de psgl-1 para el tratamiento de enfermedades inflamatorias y autoinmunes
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
PT3166636T (pt) 2014-07-08 2021-06-29 Sanford Burnham Med Res Inst Moduladores de psgl-1 e utilizações dos mesmos
IL260289B (en) 2016-01-08 2022-08-01 Bioalliance Cv Tetravalent anti-psgl-1 antibodies and uses thereof
US20170241415A1 (en) * 2016-02-19 2017-08-24 Muzan, Inc. Sanitary check valve
KR20250159733A (ko) 2017-01-11 2025-11-11 브리스톨-마이어스 스큅 컴퍼니 Psgl-1 길항제 및 그의 용도
PE20250933A1 (es) 2017-03-14 2025-04-02 Five Prime Therapeutics Inc Anticuerpos de union a vista a ph acido
BR112020019083A2 (pt) 2018-03-21 2020-12-29 Five Prime Therapeutics, Inc. Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
PE20210687A1 (es) 2018-07-11 2021-04-08 Bristol Myers Squibb Co Anticuerpos de union a vista a ph acido
CN112740043A (zh) 2018-07-20 2021-04-30 皮埃尔法布雷医药公司 Vista受体
WO2020224450A1 (en) * 2019-05-03 2020-11-12 The University Of Hong Kong Method for peritoneal metastatic cell detection and isolation thereof
CA3141334A1 (en) 2019-06-04 2020-12-10 Verseau Therapeutics, Inc. Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
WO2025168211A1 (en) * 2023-02-10 2025-08-14 Novo Nordisk A/S P-selectin peptide ligands

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5464778A (en) * 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5378464A (en) * 1989-03-08 1995-01-03 Board Of Regents Of The University Of Oklahoma Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5709859A (en) * 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US6124267A (en) * 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US6309639B1 (en) * 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US5972625A (en) * 1991-05-06 1999-10-26 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
WO1994014836A1 (en) * 1992-12-18 1994-07-07 Centocor, Inc. Peptide inhibitors of selectin binding
DE69415154T2 (de) * 1993-01-25 1999-07-29 Dana-Farber Cancer Institute, Inc., Boston, Mass. Chimäre selektine erhältlich durch domänenaustauch und ihre verwendungen
WO1995014787A1 (en) * 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
US5686426A (en) * 1994-11-17 1997-11-11 Bristol-Myers Squibb Company Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors
KR100523506B1 (en) 1995-08-03 2005-10-24 Peptide and O-glycan inhibitors of selectin mediated inflammation
JPH09227410A (ja) 1996-02-21 1997-09-02 Sumitomo Pharmaceut Co Ltd 臓器移植拒絶反応の抑制剤
WO1999043353A2 (en) * 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
CA2347119A1 (en) 1998-10-30 2000-05-11 Genetics Institute, Inc. Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists
US20040002450A1 (en) * 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
EP1406930A4 (en) 2000-12-29 2007-01-10 Savient Pharmaceuticals Inc "ISOLATED MOLECULES WITH SULFATED GROUPING CONTAINING EPITOPES, ANTIBODIES AGAINST SUCH EPITOPES AND USES THEREOF"
US20040001839A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) * 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US20050152906A1 (en) * 2003-06-30 2005-07-14 Avigdor Levanon Specific human antibodies
UY28886A1 (es) 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
ES2655833T3 (es) 2004-05-11 2018-02-21 AbGenomics Coöperatief U.A. Epítopos que inducen la muerte de células T
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF

Also Published As

Publication number Publication date
NO20130069L (no) 2004-02-24
US20090304709A1 (en) 2009-12-10
WO2003013603A1 (en) 2003-02-20
CY1112966T1 (el) 2016-04-13
NZ531199A (en) 2004-11-26
IL160168A0 (en) 2004-07-25
WO2003013603A8 (en) 2004-06-10
CY1108701T1 (el) 2014-04-09
IL204030A (en) 2014-11-30
US8298540B2 (en) 2012-10-30
CN1304051C (zh) 2007-03-14
US20030049252A1 (en) 2003-03-13
US8557579B2 (en) 2013-10-15
NO20040460L (no) 2004-02-24
KR20040054670A (ko) 2004-06-25
PT1411982E (pt) 2008-12-24
IL160168A (en) 2011-02-28
JP2012092144A (ja) 2012-05-17
EP1985634A1 (en) 2008-10-29
CA2428822C (en) 2014-10-28
ATE411045T1 (de) 2008-10-15
EP1985634B1 (en) 2011-11-02
KR100850731B1 (ko) 2008-08-06
IL204030A0 (en) 2011-08-01
CN101045161B (zh) 2010-06-16
EP1411982B1 (en) 2008-10-15
HK1124624A1 (en) 2009-07-17
CN1473052A (zh) 2004-02-04
JP2004521958A (ja) 2004-07-22
IL210557A0 (en) 2011-03-31
ES2316569T3 (es) 2009-04-16
NO333456B1 (no) 2013-06-10
JP4815101B2 (ja) 2011-11-16
ES2376948T3 (es) 2012-03-21
US20130011861A1 (en) 2013-01-10
PT1985634E (pt) 2012-02-07
DE60229394D1 (en) 2008-11-27
US7744888B2 (en) 2010-06-29
AU2002305041B2 (en) 2005-11-10
CN101045161A (zh) 2007-10-03
JP2008260759A (ja) 2008-10-30
DK1411982T3 (da) 2009-02-16
EP1411982A4 (en) 2004-10-06
TWI327070B (en) 2010-07-11
EP1411982A1 (en) 2004-04-28
CA2428822A1 (en) 2003-02-20
NO334850B1 (no) 2014-06-16
MXPA04001047A (es) 2005-02-17
HK1065489A1 (en) 2005-02-25
ATE531734T1 (de) 2011-11-15

Similar Documents

Publication Publication Date Title
CY1112966T1 (el) Αντισωμα δεσμευον το γλυκοπρωτεϊνικο προσδεμα 1 της p-σελεκτινης (ρsgl-1) για χρηση στην αγωγη αλλεργικης νοσου
WO2005027831A3 (en) Modulators of p-selectin glycoprotein ligand 1
ECSP066297A (es) Anticuerpos contra interleucina 22 y usos de los mismos
AR043616A1 (es) Anticuerpos contra receptor humano il-21 y usos de los mismos
DE60325189D1 (de) Wasserfilter
ATE483472T1 (de) Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
RU2599417C3 (ru) Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
DE69942671D1 (de) Humanisierte antikoerper gegen gamma-interferon
WO2004043361A3 (en) Compositions and methods for the treatment of natural killer cell related diseases
WO2003048327A3 (en) Anti-cd45rb antibodies for use in treating autoimmune disease and transplant rejection
ATE491019T1 (de) Kombinationen aus anti-dr5-antikörpern und anti- dr4-antikörpern und weiteren therapeutischen agentien
PT966485E (pt) Domínios de igg2 mutados não activantes e anticorpos anti-cd3 incorporando os mesmos
JOP20220204B1 (ar) الأجسام المضادة لـ cd19 البشرية
EP1660128A4 (en) ANTI-CORR ANTI-BODIES FOR THE TREATMENT OF AUTO / ALLO-IMMUNE DISORDERS
ES2054667T3 (es) Anticuerpos monoclonales contra c5a y des-arg74-c5a, su produccion y uso.
DK1028738T3 (da) Anvendelse af cytokiner og mitogener til at inhibere patologiske immunresponser
DE60042941D1 (de) Verwendung von anti-cd3 monoklonale antikörper und il-5 zur behandlung von autoimmunkrankheiten
SG146670A1 (en) Modulators of p-selectin glycoprotein ligand 1
TW200507751A (en) Nematicidal compositions and methods
ATE278461T1 (de) Mikropartikel hergestellt aus cycloolefincopolymeren und deren verwendung zur kontrollierten wirkstofffreigabe
DK1377667T3 (da) Fusionsproteiner til specifik behandling af cancer og autoimmunsygdomme
ATE392150T1 (de) Verfahren und formulierungen, die sich für die reduktion des cholesteringehalts von eigelb eignen
UA40213A (uk) Спосіб індивідуальної оцінки ефективності сорбенту
ATE104147T1 (de) Verwendung von inositol-triphosphat zur behandlung von metallvergiftung.